Hims & Hers Health, Inc. (NYSE: HIMS) CEO Andrew Dudum disposed of 78,859 shares of Class A Common Stock on August 14, according to a recent SEC Form 4 filing.
The transaction carried a total value of approximately $2.2 million, based on a weighted average sale price of $28.15 per share at the time of execution.
The disposition was non-discretionary, executed solely to cover mandatory tax withholding obligations connected to the quarterly vesting of Restricted Stock Units.
This type of administrative transaction is standard practice and does not reflect any view by the CEO on the company’s valuation or future performance prospects.
Following the transaction, Dudum’s directly held shares fell to 1,033,177, representing a roughly 7% reduction in his direct holdings.
His total equity position, including indirect holdings across eight separate trust and family entities, remains substantial at approximately 9.7 million shares, valued at around $272.32 million.
Those indirect holdings are managed through entities including the AD 2022 GRAT, the Dudum Family Community Property Trust, the Dudum Legacy 2021 Trust, and the AD 2025 GRAT, among others.
The RSUs underpinning the transaction are subject to four-year service-based vesting schedules, with awards vesting in substantially equal quarterly installments throughout the period.
The disposal came just four days after Hims reported second-quarter earnings, and weeks after the Federal Trade Commission filed suit against the company on July 29, alongside Utah and Los Angeles County.
Second-quarter revenue reached $753.2 million, representing 38% year-over-year growth, and management subsequently raised the full-year revenue guidance range to between $3.1 billion and $3.3 billion.
However, gross margin declined sharply to 64% from 76% a year earlier, driven by a shift toward branded weight loss drugs and rising international revenue within the product mix.
CFO Yemi Okupe stated on the earnings call that margins “will remain below the levels we have historically achieved,” signaling that the structural shift in revenue mix is not temporary.
The company reported a net loss of $86.3 million for the quarter, which includes a $47.5 million accrual tied directly to the FTC lawsuit filed in late July.
Third-quarter revenue guidance is set between $880 million and $900 million, a figure that will be closely watched as a test of whether the current margin trade-off is delivering results.
At the most recent market close, HIMS shares traded at $28.61, giving the company a market capitalization of $6.4 billion against trailing twelve-month revenue of $2.6 billion and a net loss of $142.0 million.
The stock has posted a one-year total return of -40% as of the August 14 transaction date, reflecting ongoing investor concern over profitability and regulatory pressure in the digital health space.
Hims operates a direct-to-consumer digital health platform, connecting patients with licensed medical professionals for virtual consultations and facilitating the delivery of prescription drugs, over-the-counter products, and wellness supplements.
Long-term investors should treat Dudum’s share disposal as a routine administrative event rather than a signal, keeping focus firmly on revenue trajectory and margin recovery heading into the back half of the year.
